MC2 Therapeutics Announces FDA Acceptance of its New Drug Application for Wynzora ™ Cream for Treatment of Plaque Psoriasis

Copenhagen, November 20th, 2019 – MC2 Therapeutics, an emerging pharmaceutical company focused on novel PAD™ Technology-based topical therapies for chronic inflammatory conditions, today announced that the U.S. Food and Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news